论文部分内容阅读
To evaluate safety and therapeutic efficacy of sodium glycididazole (CMNa) combined with 131I radiotherapy for differentiated thyroid carcinoma (DTC),the 60 patients of DTC therapeutic protocols were selected and divided into 3 groups of the DTC 4.44 GBq 131I,DTC 3.70 GBq 131I,and combination of DTC 3.70 GBq 131I with CMNa,and the 20 patients of Graves’ Disease were selected as the control group.Peripheral blood was sampled at 131I pre-treatment of 1 day,and 131I post-treatment of 7,91,and 182 days,thus analyzing lymphocyte micronucleus scores and karyotyping profiles.Compared with the control group,the lymphocyte micronucleus and chromosome mutation rates in 131I treated DTC increased after post-treatment of 7 days,recovered after post-treatment of 91 days,and did not bounce after post-treatment of 182 days.The micronucleus and chromosome mutation rates in the combination of DTC 3.70 GBq 131I with CMNa showed less significant variation than other treated DTC groups.Our results demonstrate that micronucleus assay and karyotyping analysis are favorable to evaluate 131I radiotherapy for DTC.The combination of the CMNa with 131I radiotherapy was safe for DTC patients without affecting the long-term therapeutic outcomes.
To evaluate the safety and therapeutic efficacy of sodium glycididazole (CMNa) combined with 131I radiotherapy for differentiated thyroid carcinoma (DTC), the 60 patients of DTC therapeutic protocols were selected and divided into 3 groups of the DTC 4.44 GBq 131I, DTC 3.70 GBq 131I, and combination of DTC 3.70 GBq 131I with CMNa, and the 20 patients of Graves’ Disease were selected as the control group. Peripheral blood was sampled at 131 I pre-treatment of 1 day, and 131 I post-treatment of 7, 91, and 182 days, thus analyzing lymphocyte micronucleus scores and karyotyping profiles. Compared with the control group, the lymphocyte micronucleus and chromosome mutation rates in 131I treated DTC increased after post-treatment of 7 days, recovered after post-treatment of 91 days, and did not bounce after post-treatment of 182 days. The micronucleus and chromosome mutation rates in the combination of DTC 3.70 GBq 131I with CMNa showed less significant variation than other treated DTC groups. Our results demonst rate that micronucleus assay and karyotyping analysis are favorable to evaluate 131I radiotherapy for DTC. combination of the CMNa with 131I radiotherapy was safe for DTC patients without affecting the long-term therapeutic outcomes.